BRPI0906728A2 - Formulação modificadas da liberação de inibidores do reductase de hmg coa - Google Patents

Formulação modificadas da liberação de inibidores do reductase de hmg coa

Info

Publication number
BRPI0906728A2
BRPI0906728A2 BRPI0906728-0A BRPI0906728A BRPI0906728A2 BR PI0906728 A2 BRPI0906728 A2 BR PI0906728A2 BR PI0906728 A BRPI0906728 A BR PI0906728A BR PI0906728 A2 BRPI0906728 A2 BR PI0906728A2
Authority
BR
Brazil
Prior art keywords
coa reductase
release formulations
modified release
reductase inhibitors
hmg coa
Prior art date
Application number
BRPI0906728-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Sheetal Kulkarni
Srirupa Das
Ashish Ashokrao Deshmukh
Satish Kumar Dalal
Shirishkumar Kulkarni
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BRPI0906728A2 publication Critical patent/BRPI0906728A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0906728-0A 2008-01-30 2009-01-30 Formulação modificadas da liberação de inibidores do reductase de hmg coa BRPI0906728A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN145KO2008 2008-01-30
PCT/IN2009/000069 WO2009095934A1 (en) 2008-01-30 2009-01-30 Modified release formulations of hmg coa reductase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0906728A2 true BRPI0906728A2 (pt) 2015-07-07

Family

ID=40638221

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906728-0A BRPI0906728A2 (pt) 2008-01-30 2009-01-30 Formulação modificadas da liberação de inibidores do reductase de hmg coa

Country Status (8)

Country Link
US (1) US20110003837A1 (https=)
EP (1) EP2285353A1 (https=)
JP (1) JP2011510974A (https=)
AU (1) AU2009208610A1 (https=)
BR (1) BRPI0906728A2 (https=)
MX (1) MX2010008466A (https=)
WO (1) WO2009095934A1 (https=)
ZA (1) ZA201006157B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590161B2 (en) * 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) * 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
IL149422A0 (en) * 1999-11-03 2002-11-10 Smith Howard J & Ass Pty Ltd Oral pharmaceutical compositions for liver therapy
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
DE10209979A1 (de) * 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
US20050147620A1 (en) * 2004-01-05 2005-07-07 Karl Bozicevic Cinnamon formulation for reducing cholesterol and/or glucose levels
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid

Also Published As

Publication number Publication date
JP2011510974A (ja) 2011-04-07
MX2010008466A (es) 2010-10-25
US20110003837A1 (en) 2011-01-06
AU2009208610A1 (en) 2009-08-06
WO2009095934A1 (en) 2009-08-06
EP2285353A1 (en) 2011-02-23
ZA201006157B (en) 2011-05-25

Similar Documents

Publication Publication Date Title
ZA201100966B (en) Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
BRPI0906980A2 (pt) Composição de derivados e maleatados
BR112012010201A2 (pt) formulação de libertação modificada da lacosamida
BRPI0822929A2 (pt) Composições compreendendo derivados de álcool benzílico e também compostos ativos antimicrobianos
BRPI0915300A2 (pt) composto de éster boronato e composições farmaceuticas dos mesmos
DK2345410T3 (da) Farmaceutisk sammensætning til modificeret frigivelse
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
EP2142287A4 (en) INHIBITORS OF LYSINPECIFIC DEMETHYLASE
EP2533638A4 (en) NEW INHIBITORS OF S-NITROSOGLUTATHION REDUCTASE
EP2365809A4 (en) PYRAZINOPYRZINE AND DERIVATIVES AS KINASEHEMMER
EP2318007A4 (en) Novel pyrrolidemers of S-nitrosoglutathione reductase as a therapeutic agent
PT2376533T (pt) Formulação de anticorpos
EP2272817A4 (en) PAI-1 INHIBITORS
EP2515946A4 (en) NANOCONJUGATE AND NANOCONJUGATE FORMULATIONS
EP2229451A4 (en) MATERIALS AND METHOD FOR INHIBITING ANIMALS S NITROSOGLUTATHION REDUCTASE
DK2315590T3 (da) Pyrrolinhibitorer af S-nitrosoglutathionreduktase
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
EP2341773A4 (en) PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
BRPI0917210A2 (pt) exoterma controlada de formulações de cianocrilato
EP2483274A4 (en) ANTIMALARIA AGENTS AS AN INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE
EP2312939A4 (en) ANTIMICROBIAL GEL FORMULATIONS
BRPI0822782A2 (pt) composição farmacêutica que compreende rosuvastatina
BRPI0919249A2 (pt) composição de revestimento de pastilhas altamente sólidas e mácias
EP2435470A4 (en) MUTINES OF PYRROLINE-5-CARBOXYLATE REDUCTASE 1

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.